Form 4 holding
10%+ Owner
Crinetics Pharmaceuticals, Inc.
- Security class
- Common Stock
- Shares / value
- 5,321,032
- Estimated value
- $200,336,855
- Report date
- 18 Apr 2022
- Price
- $37.65
- Ownership
- Indirect
PERCEPTIVE ADVISORS LLC
Insider Reports History
- Reporting-owner location
- New York, NY
- Latest reporting-owner signature
-
Joseph Edelman
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for PERCEPTIVE ADVISORS LLC
Form 4 holding
10%+ Owner
VBI Vaccines Inc/BC
- Security class
- Common Stock
- Shares / value
- 41,440,729
- Estimated value
- $137,168,813
- Report date
- 06 Apr 2023
- Price
- $3.31
- Ownership
- Indirect
Form 4 holding
10%+ Owner
SOLENO THERAPEUTICS INC
- Security class
- Common Stock
- Shares / value
- 3,074,542
- Estimated value
- $112,175,587
- Report date
- 28 Sep 2023
- Price
- $36.49
- Ownership
- Indirect
Form 4 holding
Director
Immatics N.V.
- Security class
- Ordinary Shares, nominal value EUR 0.01 per share
- Shares / value
- 10,383,456
- Estimated value
- $102,796,214
- Report date
- 18 Mar 2026
- Price
- $9.90
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
MeiraGTx Holdings plc
- Security class
- Ordinary Shares
- Shares / value
- 10,786,658
- Estimated value
- $93,416,772
- Report date
- 17 Apr 2026
- Price
- $8.66
- Ownership
- Indirect
Form 4 holding
10%+ Owner
ALBIREO PHARMA, INC.
- Security class
- Common Stock
- Shares / value
- 1,939,723
- Estimated value
- $84,959,867
- Report date
- 13 Oct 2022
- Price
- $43.80
- Ownership
- Indirect
Form 4 holding
10%+ Owner
ADMA BIOLOGICS, INC.
- Security class
- Common Stock
- Shares / value
- 13,262,375
- Estimated value
- $59,945,935
- Report date
- 30 Sep 2021
- Price
- $4.52
- Ownership
- Indirect
Form 4 holding
Director
Astria Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 4,873,721
- Estimated value
- $58,923,287
- Report date
- 01 Feb 2024
- Price
- $12.09
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Verrica Pharmaceuticals Inc.
- Security class
- Common Stock
- Shares / value
- 7,099,182
- Estimated value
- $51,398,078
- Report date
- 29 Dec 2023
- Price
- $7.24
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Aldeyra Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 5,875,851
- Estimated value
- $27,829,793
- Report date
- 03 Apr 2025
- Price
- $4.74
- Ownership
- Indirect
Form 4 holding
10%+ Owner
AGILE THERAPEUTICS INC
- Security class
- Common Stock
- Shares / value
- 21,654,485
- Estimated value
- $18,406,312
- Report date
- 13 Oct 2021
- Price
- $0.8500
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Orchestra BioMed Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 5,292,556
- Estimated value
- $14,554,529
- Report date
- 01 Aug 2025
- Price
- $2.75
- Ownership
- Indirect
Form 4 holding
10%+ Owner
VYNE Therapeutics Inc.
- Security class
- Common Stock
- Shares / value
- 4,935,057
- Estimated value
- $11,251,930
- Report date
- 16 Aug 2021
- Price
- $2.28
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Athira Pharma, Inc.
- Security class
- Series A Warrant (right to buy)
- Shares / value
- 1,279,526
- Estimated value
- $8,124,990
- Report date
- 23 Dec 2025
- Price
- $6.35
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Athira Pharma, Inc.
- Security class
- Series B Warrant (right to buy)
- Shares / value
- 1,181,101
- Estimated value
- $7,499,991
- Report date
- 23 Dec 2025
- Price
- $6.35
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Astria Therapeutics, Inc.
- Security class
- Pre-funded Warrants (right to buy)
- Shares / value
- 921,093
- Estimated value
- $5,999,079
- Report date
- 16 Oct 2023
- Price
- $6.51
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Former 10% Owner
CARGO Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 333,333
- Estimated value
- $4,999,995
- Report date
- 14 Nov 2023
- Price
- $15.00
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Acrivon Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 3,104,139
- Estimated value
- $4,159,546
- Report date
- 01 May 2025
- Price
- $1.34
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Orchestra BioMed Holdings, Inc.
- Security class
- Pre-funded Warrants (right to buy)
- Shares / value
- 1,500,000
- Estimated value
- $4,124,849
- Report date
- 01 Aug 2025
- Price
- $2.75
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Adagio Medical Holdings, Inc.
- Security class
- Pre-Funded Warrant (right to buy)
- Shares / value
- 2,190,496
- Estimated value
- $3,505,231
- Report date
- 20 Oct 2025
- Price
- $1.60
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
Rain Therapeutics Inc.
- Security class
- Common Stock
- Shares / value
- 2,487,019
- Estimated value
- $3,009,293
- Report date
- 12 Oct 2021
- Price
- $1.21
- Ownership
- Indirect
Form 4 holding
10%+ Owner
IsoPlexis Corp
- Security class
- Common Stock
- Shares / value
- 3,554,587
- Estimated value
- $2,581,697
- Report date
- 12 Oct 2021
- Price
- $0.7263
- Ownership
- By Perceptive Life Sciences Master Fund, Ltd.
Form 4 holding
Director
Astria Therapeutics, Inc.
- Security class
- Common Warrants (right to buy)
- Shares / value
- 345,409
- Estimated value
- $2,249,994
- Report date
- 16 Oct 2023
- Price
- $6.51
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Athira Pharma, Inc.
- Security class
- Common Stock
- Shares / value
- 329,756
- Estimated value
- $2,093,950
- Report date
- 23 Dec 2025
- Price
- $6.35
- Ownership
- Indirect
Form 4 holding
10%+ Owner
CHEMBIO DIAGNOSTICS, INC.
- Security class
- Common Stock
- Shares / value
- 3,672,662
- Estimated value
- $1,652,698
- Report date
- 04 Apr 2023
- Price
- $0.4500
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Quotient Ltd
- Security class
- Ordinary Shares, nil par value
- Shares / value
- 7,945,211
- Estimated value
- $635,617
- Report date
- 31 Oct 2022
- Price
- $0.0800
- Ownership
- Indirect
Form 4 holding
10%+ Owner
IsoPlexis Corp
- Security class
- Common Stock
- Shares / value
- 335,962
- Estimated value
- $244,009
- Report date
- 12 Oct 2021
- Price
- $0.7263
- Ownership
- By Perceptive Credit Holdings III, LP
Form 4 holding
10%+ Owner
IsoPlexis Corp
- Security class
- Common Stock
- Shares / value
- 204,949
- Estimated value
- $148,854
- Report date
- 12 Oct 2021
- Price
- $0.7263
- Ownership
- By PCOF EQ AIV III, LP
Form 4 holding
Director, 10%+ Owner
LianBio
- Security class
- Ordinary Shares
- Shares / value
- 17,082
- Estimated value
- $81,310
- Report date
- 15 Feb 2024
- Price
- $4.76
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Lyra Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 14,026
- Estimated value
- $54,702
- Report date
- 13 Nov 2025
- Price
- $3.90
- Ownership
- Indirect
Form 4 holding
Director
Cerevel Therapeutics Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 20 Feb 2024
- Price
- $41.54
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Adagio Medical Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 9,675,684
- Estimated value
- Report date
- 22 Jan 2025
- Price
- Ownership
- Direct
Form 4 holding
Director, 10%+ Owner
Solid Biosciences Inc.
- Security class
- Pre-Funded Warrant (right to buy)
- Shares / value
- 8,912,655
- Estimated value
- Report date
- 09 Mar 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
Kardigan, Inc.
- Security class
- Common Stock
- Shares / value
- 5,740,466
- Estimated value
- Report date
- 17 Jun 2026
- Price
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Athira Pharma, Inc.
- Security class
- Pre-Funded Warrant (right to buy)
- Shares / value
- 5,502,402
- Estimated value
- Report date
- 23 Dec 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
LianBio
- Security class
- American Depository Shares
- Shares / value
- 3,728,491
- Estimated value
- Report date
- 15 Feb 2024
- Price
- Ownership
- Indirect
Form 4 holding
10%+ Owner
Landos Biopharma, Inc.
- Security class
- Pre-funded Warrant
- Shares / value
- 3,636,363
- Estimated value
- Report date
- 10 Jan 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
LEAP THERAPEUTICS, INC.
- Security class
- Warrants (right to buy)
- Shares / value
- 3,508,771
- Estimated value
- Report date
- 24 Sep 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
AGILE THERAPEUTICS INC
- Security class
- Warrants (right to buy)
- Shares / value
- 2,687,280
- Estimated value
- Report date
- 13 Oct 2021
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Adagio Medical Holdings, Inc.
- Security class
- Tranche A Warrant ("Common Warrant" right to buy)
- Shares / value
- 1,344,999
- Estimated value
- Report date
- 20 Oct 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock or Pre-Funded Warrants
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Adagio Medical Holdings, Inc.
- Security class
- Tranche B Warrant ("Common Warrant" right to buy)
- Shares / value
- 1,344,999
- Estimated value
- Report date
- 20 Oct 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock or Pre-Funded Warrants
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Adagio Medical Holdings, Inc.
- Security class
- Tranche C Warrant ("Common Warrant" right to buy)
- Shares / value
- 1,344,999
- Estimated value
- Report date
- 20 Oct 2025
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock or Pre-Funded Warrants
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MeiraGTx Holdings plc
- Security class
- Warrant (Right to Buy)
- Shares / value
- 300,000
- Estimated value
- Report date
- 25 Mar 2026
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
10%+ Owner
SOLENO THERAPEUTICS INC
- Security class
- Pre-funded warrants (right to buy)
- Shares / value
- 250,000
- Estimated value
- Report date
- 28 Sep 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Adagio Medical Holdings, Inc.
- Security class
- Common Stock
- Shares / value
- 200,902
- Estimated value
- Report date
- 22 Jan 2025
- Price
- Ownership
- Indirect
Form 4 holding
Director, 10%+ Owner
Solid Biosciences Inc.
- Security class
- Director Stock Option (Right to Buy)
- Shares / value
- 77,500
- Estimated value
- Report date
- 10 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
MeiraGTx Holdings plc
- Security class
- Restricted Share Units
- Shares / value
- 60,000
- Estimated value
- Report date
- 11 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
Director
Immatics N.V.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 48,000
- Estimated value
- Report date
- 16 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Form 4 holding
Director, 10%+ Owner
Nautilus Biotechnology, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 45,000
- Estimated value
- Report date
- 14 Jun 2024
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
LeonaBio, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 28,000
- Estimated value
- Report date
- 23 Jun 2026
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Former 10% Owner
CARGO Therapeutics, Inc.
- Security class
- Series A-1 Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 14 Nov 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
IsoPlexis Corp
- Security class
- Series D Redeemable Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 12 Oct 2021
- Price
- Ownership
- By PCOF EQ AIV III, LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
IsoPlexis Corp
- Security class
- Series D Redeemable Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 12 Oct 2021
- Price
- Ownership
- By Perceptive Credit Holdings III, LP
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
IsoPlexis Corp
- Security class
- Series D Redeemable Convertible Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 12 Oct 2021
- Price
- Ownership
- By Perceptive Life Sciences Master Fund, Ltd.
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director, 10%+ Owner
LianBio
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 15 Feb 2024
- Price
- Ownership
- Indirect
- Underlying class
- Ordinary Shares
- Underlying amount
Insider Reports Filed by PERCEPTIVE ADVISORS LLC
4
LONA
LeonaBio, Inc.
- Report period
- 23 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jul 2026, 18:48
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
KARD
Kardigan, Inc.
- Report period
- 17 Jun 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2026, 11:09
- Role
- Director
- Next action
- Open filing details
4
IMTX
Immatics N.V.
- Report period
- 16 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2026, 16:30
- Role
- Director
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 11 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2026, 16:30
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 10 Jun 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Jun 2026, 16:05
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
IMTX
Immatics N.V.
- Report period
- 18 Mar 2026
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 Mar 2026, 16:00
- Role
- Director
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 09 Mar 2026
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Mar 2026, 16:00
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 31 Dec 2025
- Transactions
- 1
- Transaction value
- -$18,193,000
- Accepted by SEC
- 02 Jan 2026, 16:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ATHA
Athira Pharma, Inc.
- Report period
- 23 Dec 2025
- Transactions
- 9
- Transaction value
- +$82,498,150
- Accepted by SEC
- 23 Dec 2025, 17:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
LYRA
Lyra Therapeutics, Inc.
- Report period
- 11 Nov 2025
- Transactions
- 6
- Transaction value
- -$182,515
- Accepted by SEC
- 13 Nov 2025, 17:07
- Role
- 10%+ Owner
- Next action
- Open filing details
4
LYRA
Lyra Therapeutics, Inc.
- Report period
- 06 Nov 2025
- Transactions
- 6
- Transaction value
- -$344,219
- Accepted by SEC
- 10 Nov 2025, 17:08
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ADGM
Adagio Medical Holdings, Inc.
- Report period
- 20 Oct 2025
- Transactions
- 4
- Transaction value
- +$4,250,092
- Accepted by SEC
- 22 Oct 2025, 16:33
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
OBIO
Orchestra BioMed Holdings, Inc.
- Report period
- 01 Aug 2025
- Transactions
- 2
- Transaction value
- +$6,049,850
- Accepted by SEC
- 05 Aug 2025, 10:46
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 12 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2025, 16:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 12 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2025, 17:05
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 30 Apr 2025
- Transactions
- 2
- Transaction value
- -$1,017,919
- Accepted by SEC
- 01 May 2025, 19:07
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 25 Apr 2025
- Transactions
- 3
- Transaction value
- -$2,744,946
- Accepted by SEC
- 29 Apr 2025, 19:26
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 03 Apr 2025
- Transactions
- 1
- Transaction value
- -$4,828,000
- Accepted by SEC
- 07 Apr 2025, 18:43
- Role
- 10%+ Owner
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 19 Feb 2025
- Transactions
- 1
- Transaction value
- +$20,150,000
- Accepted by SEC
- 21 Feb 2025, 16:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ADGM
Adagio Medical Holdings, Inc.
- Report period
- 22 Jan 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 14 Feb 2025, 16:35
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 12 Aug 2024
- Transactions
- 1
- Transaction value
- +$5,000,000
- Accepted by SEC
- 14 Aug 2024, 18:54
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
ADGM
Aja Holdco, Inc.
- Report period
- 31 Jul 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 01 Aug 2024, 17:18
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
OBIO
Orchestra BioMed Holdings, Inc.
- Report period
- 11 Jul 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 17 Jul 2024, 16:38
- Role
- 10%+ Owner
- Next action
- Open filing details
3
VAPOTHERM INC
- Report period
- 17 Jun 2024
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2024, 19:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NAUT
Nautilus Biotechnology, Inc.
- Report period
- 14 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2024, 18:02
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 11 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 19 Nov 2024, 16:20
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 06 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 07 Jun 2024, 18:48
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 11 Apr 2024
- Transactions
- 1
- Transaction value
- +$20,000,500
- Accepted by SEC
- 15 Apr 2024, 08:53
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 04 Apr 2024
- Transactions
- 2
- Transaction value
- +$833,867
- Accepted by SEC
- 08 Apr 2024, 17:32
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 01 Apr 2024
- Transactions
- 3
- Transaction value
- +$1,934,505
- Accepted by SEC
- 03 Apr 2024, 17:22
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Cerevel Therapeutics Holdings, Inc.
- Report period
- 20 Feb 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Feb 2024, 16:54
- Role
- Director
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 15 Feb 2024
- Transactions
- 6
- Transaction value
- -$3.36
- Accepted by SEC
- 20 Feb 2024, 17:25
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ATXS
Astria Therapeutics, Inc.
- Report period
- 01 Feb 2024
- Transactions
- 1
- Transaction value
- +$29,999,522
- Accepted by SEC
- 05 Feb 2024, 17:02
- Role
- Director
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 11 Jan 2024
- Transactions
- 1
- Transaction value
- +$18,861,243
- Accepted by SEC
- 12 Jan 2024, 17:15
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VRCA
Verrica Pharmaceuticals Inc.
- Report period
- 27 Dec 2023
- Transactions
- 3
- Transaction value
- +$2,305,132
- Accepted by SEC
- 29 Dec 2023, 17:27
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ATHA
Athira Pharma, Inc.
- Report period
- 27 Dec 2023
- Transactions
- 3
- Transaction value
- +$1,462,895
- Accepted by SEC
- 29 Dec 2023, 17:24
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VRCA
Verrica Pharmaceuticals Inc.
- Report period
- 21 Dec 2023
- Transactions
- 3
- Transaction value
- +$3,256,191
- Accepted by SEC
- 26 Dec 2023, 19:21
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ATXS
Astria Therapeutics, Inc.
- Report period
- 21 Dec 2023
- Transactions
- 1
- Transaction value
- +$4,588,000
- Accepted by SEC
- 22 Dec 2023, 14:51
- Role
- Director
- Next action
- Open filing details
4
VRCA
Verrica Pharmaceuticals Inc.
- Report period
- 15 Dec 2023
- Transactions
- 3
- Transaction value
- +$6,941,716
- Accepted by SEC
- 19 Dec 2023, 17:52
- Role
- 10%+ Owner
- Next action
- Open filing details
4
CRGX
CARGO Therapeutics, Inc.
- Report period
- 14 Nov 2023
- Transactions
- 4
- Transaction value
- +$9,999,990
- Accepted by SEC
- 14 Nov 2023, 16:32
- Role
- Former 10% Owner
- Next action
- Open filing details
3
CRGX
CARGO Therapeutics, Inc.
- Report period
- 09 Nov 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 09 Nov 2023, 18:37
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 16 Oct 2023
- Transactions
- 2
- Transaction value
- -$4,453,308
- Accepted by SEC
- 18 Oct 2023, 17:15
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ATXS
Astria Therapeutics, Inc.
- Report period
- 16 Oct 2023
- Transactions
- 6
- Transaction value
- +$25,998,150
- Accepted by SEC
- 18 Oct 2023, 16:11
- Role
- Director
- Next action
- Open filing details
4
Cerevel Therapeutics Holdings, Inc.
- Report period
- 16 Oct 2023
- Transactions
- 1
- Transaction value
- +$19,999,990
- Accepted by SEC
- 17 Oct 2023, 16:53
- Role
- Director
- Next action
- Open filing details
4
SLNO
SOLENO THERAPEUTICS INC
- Report period
- 26 Sep 2023
- Transactions
- 16
- Transaction value
- +$20,111,416
- Accepted by SEC
- 28 Sep 2023, 15:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 21 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 23 Jun 2023, 16:09
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NAUT
Nautilus Biotechnology, Inc.
- Report period
- 15 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 Jun 2023, 21:07
- Role
- Director
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 08 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2023, 16:07
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 06 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 08 Jun 2023, 16:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLNO
SOLENO THERAPEUTICS INC
- Report period
- 02 Jun 2023
- Transactions
- 3
- Transaction value
- +$853,681
- Accepted by SEC
- 06 Jun 2023, 16:16
- Role
- 10%+ Owner
- Next action
- Open filing details
4
LYRA
Lyra Therapeutics, Inc.
- Report period
- 31 May 2023
- Transactions
- 2
- Transaction value
- +$8,999,999
- Accepted by SEC
- 02 Jun 2023, 16:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLNO
SOLENO THERAPEUTICS INC
- Report period
- 30 May 2023
- Transactions
- 3
- Transaction value
- +$188,175
- Accepted by SEC
- 01 Jun 2023, 17:41
- Role
- 10%+ Owner
- Next action
- Open filing details
4
SLNO
SOLENO THERAPEUTICS INC
- Report period
- 24 May 2023
- Transactions
- 3
- Transaction value
- +$449,825
- Accepted by SEC
- 26 May 2023, 17:57
- Role
- 10%+ Owner
- Next action
- Open filing details
4
SLNO
SOLENO THERAPEUTICS INC
- Report period
- 19 May 2023
- Transactions
- 3
- Transaction value
- +$406,075
- Accepted by SEC
- 23 May 2023, 18:47
- Role
- 10%+ Owner
- Next action
- Open filing details
3
SLNO
SOLENO THERAPEUTICS INC
- Report period
- 11 May 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 May 2023, 16:31
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 05 May 2023
- Transactions
- 1
- Transaction value
- +$25,000,000
- Accepted by SEC
- 15 May 2023, 20:12
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
CHEMBIO DIAGNOSTICS, INC.
- Report period
- 04 Apr 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 06 Apr 2023, 21:30
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VBI Vaccines Inc/BC
- Report period
- 04 Apr 2023
- Transactions
- 3
- Transaction value
- -$1,475,605
- Accepted by SEC
- 06 Apr 2023, 17:51
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Landos Biopharma, Inc.
- Report period
- 10 Jan 2023
- Transactions
- 2
- Transaction value
- +$16,690,909
- Accepted by SEC
- 11 Jan 2023, 17:45
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ATXS
Astria Therapeutics, Inc.
- Report period
- 19 Dec 2022
- Transactions
- 1
- Transaction value
- +$9,999,998
- Accepted by SEC
- 21 Dec 2022, 15:52
- Role
- Director
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 13 Dec 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Dec 2022, 16:34
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 02 Dec 2022
- Transactions
- 3
- Transaction value
- +$15,249,996
- Accepted by SEC
- 06 Dec 2022, 15:41
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
ACRV
Acrivon Therapeutics, Inc.
- Report period
- 17 Nov 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 18 Nov 2022, 15:34
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Quotient Ltd
- Report period
- 31 Oct 2022
- Transactions
- 1
- Transaction value
- -$660,449
- Accepted by SEC
- 02 Nov 2022, 16:58
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALBIREO PHARMA, INC.
- Report period
- 11 Oct 2022
- Transactions
- 7
- Transaction value
- -$9,505,547
- Accepted by SEC
- 13 Oct 2022, 19:37
- Role
- 10%+ Owner
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 18 Aug 2022
- Transactions
- 1
- Transaction value
- +$2,395,776
- Accepted by SEC
- 22 Aug 2022, 09:17
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Cerevel Therapeutics Holdings, Inc.
- Report period
- 16 Aug 2022
- Transactions
- 2
- Transaction value
- +$149,875,000
- Accepted by SEC
- 18 Aug 2022, 17:10
- Role
- Director
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 09 Aug 2022
- Transactions
- 2
- Transaction value
- +$867,750
- Accepted by SEC
- 11 Aug 2022, 16:08
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 08 Aug 2022
- Transactions
- 1
- Transaction value
- +$702,280
- Accepted by SEC
- 10 Aug 2022, 16:10
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 05 Aug 2022
- Transactions
- 1
- Transaction value
- +$979,950
- Accepted by SEC
- 09 Aug 2022, 16:08
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 04 Aug 2022
- Transactions
- 1
- Transaction value
- +$586,767
- Accepted by SEC
- 08 Aug 2022, 16:09
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 03 Aug 2022
- Transactions
- 1
- Transaction value
- +$584,000
- Accepted by SEC
- 05 Aug 2022, 16:10
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 02 Aug 2022
- Transactions
- 7
- Transaction value
- $0
- Accepted by SEC
- 23 Apr 2026, 20:59
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 02 Aug 2022
- Transactions
- 1
- Transaction value
- +$2,305,350
- Accepted by SEC
- 04 Aug 2022, 16:10
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 01 Aug 2022
- Transactions
- 1
- Transaction value
- +$728,134
- Accepted by SEC
- 03 Aug 2022, 17:16
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 29 Jul 2022
- Transactions
- 1
- Transaction value
- +$1,117,279
- Accepted by SEC
- 02 Aug 2022, 16:27
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ALDX
Aldeyra Therapeutics, Inc.
- Report period
- 28 Jul 2022
- Transactions
- 1
- Transaction value
- +$596,960
- Accepted by SEC
- 01 Aug 2022, 17:37
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VRCA
Verrica Pharmaceuticals Inc.
- Report period
- 05 Jul 2022
- Transactions
- 1
- Transaction value
- +$2,999,999
- Accepted by SEC
- 05 Jul 2022, 17:32
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ATHA
Athira Pharma, Inc.
- Report period
- 29 Jun 2022
- Transactions
- 2
- Transaction value
- +$4,100,372
- Accepted by SEC
- 01 Jul 2022, 14:24
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 23 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 27 Jun 2022, 17:38
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NAUT
Nautilus Biotechnology, Inc.
- Report period
- 15 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2022, 17:43
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 07 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2022, 18:11
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
SLDB
Solid Biosciences Inc.
- Report period
- 07 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2022, 18:20
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 26 May 2022
- Transactions
- 1
- Transaction value
- +$215,970
- Accepted by SEC
- 27 May 2022, 10:06
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 23 May 2022
- Transactions
- 3
- Transaction value
- +$442,364
- Accepted by SEC
- 25 May 2022, 18:51
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
ATHA
Athira Pharma, Inc.
- Report period
- 20 May 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 27 May 2022, 17:19
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CRNX
Crinetics Pharmaceuticals, Inc.
- Report period
- 18 Apr 2022
- Transactions
- 1
- Transaction value
- +$3,499,983
- Accepted by SEC
- 18 Apr 2022, 17:39
- Role
- 10%+ Owner
- Next action
- Open filing details
4
LYRA
Lyra Therapeutics, Inc.
- Report period
- 12 Apr 2022
- Transactions
- 1
- Transaction value
- +$24,999,997
- Accepted by SEC
- 14 Apr 2022, 16:53
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
NAUT
Nautilus Biotechnology, Inc.
- Report period
- 08 Dec 2021
- Transactions
- 1
- Transaction value
- +$1,072,000
- Accepted by SEC
- 10 Dec 2021, 15:05
- Role
- Director
- Next action
- Open filing details
4
VBI Vaccines Inc/BC
- Report period
- 01 Dec 2021
- Transactions
- 1
- Transaction value
- -$8,961,703
- Accepted by SEC
- 03 Dec 2021, 17:22
- Role
- 10%+ Owner
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 03 Nov 2021
- Transactions
- 2
- Transaction value
- +$36,270,200
- Accepted by SEC
- 05 Nov 2021, 13:47
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
LIANY
LianBio
- Report period
- 01 Nov 2021
- Transactions
- 12
- Transaction value
- +$3,210,000
- Accepted by SEC
- 03 Nov 2021, 18:59
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
3
LIANY
LianBio
- Report period
- 29 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 29 Oct 2021, 18:46
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
CRNX
Crinetics Pharmaceuticals, Inc.
- Report period
- 25 Oct 2021
- Transactions
- 1
- Transaction value
- +$23,760,000
- Accepted by SEC
- 25 Oct 2021, 14:47
- Role
- 10%+ Owner
- Next action
- Open filing details
4
AGILE THERAPEUTICS INC
- Report period
- 13 Oct 2021
- Transactions
- 2
- Transaction value
- +$4,874,376
- Accepted by SEC
- 15 Oct 2021, 16:05
- Role
- 10%+ Owner
- Next action
- Open filing details
4
IsoPlexis Corp
- Report period
- 12 Oct 2021
- Transactions
- 7
- Transaction value
- +$12,750,000
- Accepted by SEC
- 14 Oct 2021, 17:07
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Rain Therapeutics Inc.
- Report period
- 07 Oct 2021
- Transactions
- 7
- Transaction value
- -$667,479
- Accepted by SEC
- 13 Oct 2021, 17:47
- Role
- 10%+ Owner
- Next action
- Open filing details
3
IsoPlexis Corp
- Report period
- 07 Oct 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 07 Oct 2021, 17:27
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ADMA
ADMA BIOLOGICS, INC.
- Report period
- 28 Sep 2021
- Transactions
- 3
- Transaction value
- -$299,236
- Accepted by SEC
- 30 Sep 2021, 19:27
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ADMA
ADMA BIOLOGICS, INC.
- Report period
- 24 Sep 2021
- Transactions
- 2
- Transaction value
- -$622,500
- Accepted by SEC
- 29 Sep 2021, 19:18
- Role
- 10%+ Owner
- Next action
- Open filing details
4
LPTX
LEAP THERAPEUTICS, INC.
- Report period
- 24 Sep 2021
- Transactions
- 1
- Transaction value
- +$9,996,489
- Accepted by SEC
- 28 Sep 2021, 16:21
- Role
- 10%+ Owner
- Next action
- Open filing details
4
ADMA
ADMA BIOLOGICS, INC.
- Report period
- 23 Sep 2021
- Transactions
- 1
- Transaction value
- -$990,600
- Accepted by SEC
- 28 Sep 2021, 16:18
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Landos Biopharma, Inc.
- Report period
- 27 Aug 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 31 Aug 2021, 21:31
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
Cerevel Therapeutics Holdings, Inc.
- Report period
- 26 Aug 2021
- Transactions
- 1
- Transaction value
- +$2,057,061
- Accepted by SEC
- 31 Aug 2021, 14:15
- Role
- Director
- Next action
- Open filing details
4
Cerevel Therapeutics Holdings, Inc.
- Report period
- 23 Aug 2021
- Transactions
- 3
- Transaction value
- +$4,833,885
- Accepted by SEC
- 25 Aug 2021, 19:14
- Role
- Director
- Next action
- Open filing details
4
ADMA
ADMA BIOLOGICS, INC.
- Report period
- 17 Aug 2021
- Transactions
- 3
- Transaction value
- -$2,333,781
- Accepted by SEC
- 19 Aug 2021, 19:58
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VYNE
VYNE Therapeutics Inc.
- Report period
- 16 Aug 2021
- Transactions
- 1
- Transaction value
- -$435,000
- Accepted by SEC
- 18 Aug 2021, 19:19
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VYNE
VYNE Therapeutics Inc.
- Report period
- 13 Aug 2021
- Transactions
- 1
- Transaction value
- -$460,000
- Accepted by SEC
- 17 Aug 2021, 16:46
- Role
- 10%+ Owner
- Next action
- Open filing details
4
VYNE
VYNE Therapeutics Inc.
- Report period
- 12 Aug 2021
- Transactions
- 1
- Transaction value
- -$755,740
- Accepted by SEC
- 16 Aug 2021, 18:24
- Role
- 10%+ Owner
- Next action
- Open filing details
4
Cerevel Therapeutics Holdings, Inc.
- Report period
- 07 Jul 2021
- Transactions
- 1
- Transaction value
- +$5,000,000
- Accepted by SEC
- 09 Jul 2021, 18:39
- Role
- Director
- Next action
- Open filing details
4
VBI Vaccines Inc/BC
- Report period
- 29 Jun 2021
- Transactions
- 2
- Transaction value
- -$2,455,777
- Accepted by SEC
- 30 Jun 2021, 16:40
- Role
- 10%+ Owner
- Next action
- Open filing details
4
MGTX
MeiraGTx Holdings plc
- Report period
- 10 Jun 2021
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2021, 17:23
- Role
- Director, 10%+ Owner
- Next action
- Open filing details
4
VBI Vaccines Inc/BC
- Report period
- 09 Jun 2021
- Transactions
- 6
- Transaction value
- -$1,002
- Accepted by SEC
- 11 Jun 2021, 18:41
- Role
- 10%+ Owner
- Next action
- Open filing details
4
NAUT
ARYA Sciences Acquisition Corp III
- Report period
- 03 Jun 2021
- Transactions
- 1
- Transaction value
- +$3,317,002
- Accepted by SEC
- 03 Jun 2021, 18:55
- Role
- Director
- Next action
- Open filing details
4
ATHA
Athira Pharma, Inc.
- Report period
- 28 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 01 Jun 2021, 19:58
- Role
- Director
- Next action
- Open filing details
4
NAUT
Nautilus Biotechnology, Inc.
- Report period
- 24 May 2021
- Transactions
- 3
- Transaction value
- +$55,070,983
- Accepted by SEC
- 11 Jun 2021, 17:45
- Role
- Former Director
- Next action
- Open filing details
4
NAUT
ARYA Sciences Acquisition Corp III
- Report period
- 20 May 2021
- Transactions
- 1
- Transaction value
- +$1,607,246
- Accepted by SEC
- 24 May 2021, 18:49
- Role
- Director
- Next action
- Open filing details
3
NAUT
ARYA Sciences Acquisition Corp III
- Report period
- 20 May 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 24 May 2021, 18:48
- Role
- Director
- Next action
- Open filing details
4
VYNE
VYNE Therapeutics Inc.
- Report period
- 06 May 2021
- Transactions
- 1
- Transaction value
- -$3,670,000
- Accepted by SEC
- 07 May 2021, 17:31
- Role
- 10%+ Owner
- Next action
- Open filing details